<p>Capital &amp; Planning LLC 在最近向美国证券交易委员会提交的 13F 文件中表示，在第二季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股减少了 81.2%。该公司在季度内出售了 5,000 股后，持有 1,155 股艾伯维的股票。根据其最近的 SEC 文件，Capital &amp; Planning LLC 在艾伯维的持股价值为 214,000 美元。</p>
<ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
<p>其他机构投资者和对冲基金最近也调整了对该公司的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在艾伯维的持股增加了 0.5%。先锋集团目前持有 173,917,865 股艾伯维的股票，价值 36,439,271,000 美元，此前在该期间又购买了 845,787 股。北方信托公司（Northern Trust Corp）在第一季度将其在艾伯维的持股增加了 0.9%。北方信托公司目前持有 22,013,920 股艾伯维的股票，价值 4,612,357,000 美元，此前在该期间又购买了 189,294 股。高盛集团（Goldman Sachs Group Inc.）在第一季度将其在艾伯维的持股增加了 31.6%。高盛集团目前持有 14,646,908 股艾伯维的股票，价值 3,068,820,000 美元，此前在该期间又购买了 3,519,187 股。瑞银资产管理（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度将其在艾伯维的持股增加了 5.9%。瑞银资产管理目前持有 12,771,854 股艾伯维的股票，价值 2,675,959,000 美元，此前在该期间又收购了 713,148 股。最后，Dimensional Fund Advisors LP 在第一季度将其在艾伯维的持股增加了 0.5%。Dimensional Fund Advisors LP 目前持有 9,413,033 股艾伯维的股票，价值 1,972,050,000 美元，此前在该期间又收购了 45,871 股。70.23% 的股票由机构投资者持有。</p>
<h2>分析师评级上调与下调</h2>
<p>多家研究公司最近对 ABBV 进行了评估。富国银行（Wells Fargo &amp; Company）在 9 月 12 日的研究报告中将艾伯维的目标股价从 240.00 美元上调至 260.00 美元，并给予该公司 “增持” 评级。贝伦贝格银行（Berenberg Bank）在 9 月 17 日的研究报告中将艾伯维的评级从 “持有” 上调至 “买入”，并将其目标股价从 170.00 美元上调至 270.00 美元。Cantor Fitzgerald 在 9 月 15 日的研究报告中将艾伯维的目标股价从 215.00 美元上调至 245.00 美元，并给予该公司 “增持” 评级。Evercore ISI 在 9 月 22 日的报告中将艾伯维的目标股价从 207.00 美元上调至 222.00 美元，并给予该公司 “跑赢大盘” 评级。最后，派珀·桑德勒（Piper Sandler）在 8 月 12 日的报告中开始覆盖艾伯维的股票。他们给予 “增持” 评级，并设定 231.00 美元的目标股价。四位股票研究分析师对该股票给予强烈买入评级，十七位给予买入评级，八位给予持有评级。根据 MarketBeat 的数据，艾伯维的共识评级为 “适度买入”，共识目标价为 223.52 美元。</p>
<ul>
<li>艾伯维股票关注突破，管道与利润增长</li>
</ul>
<p><strong>获取我们对 ABBV 的最新股票分析</strong></p>
<h2>艾伯维股票下跌 3.0%</h2>
<p>艾伯维（ABBV）股票在周五开盘价为 236.98 美元。艾伯维公司 12 个月低点为 163.81 美元，12 个月高点为 244.81 美元。该公司的 50 日移动平均线为 209.90 美元，200 日移动平均线为 195.87 美元。该股票的市值为 4186.3 亿美元，市盈率为 112.85，市盈增长比率为 1.43，贝塔值为 0.51。该公司的流动比率为 0.74，速动比率为 0.61，债务与股本比率为 44.14。</p>
<ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日宣布了其财报。该公司报告本季度每股收益为 2.97 美元，低于共识预期的 3.24 美元，差额为 0.27 美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。该公司本季度的收入为 154.2 亿美元，而共识预期为 149.3 亿美元。去年同期，该公司的每股收益为 2.65 美元。与去年同期相比，该公司的季度收入增长了 6.6%。股票研究分析师预测，艾伯维公司今年将发布 12.31 美元的每股收益。</p>
<h2>艾伯维宣布分红</h2>
<p>该公司最近还宣布了季度分红，将于 11 月 14 日（星期五）支付。10 月 15 日（星期三）的登记投资者将获得 1.64 美元的分红。除息日为 10 月 15 日（星期三）。这代表着年化分红为 6.56 美元，分红收益率为 2.8%。艾伯维的分红支付比率（DPR）目前为 312.38%。</p>
<h2>内部人士下注</h2>
<p>在其他艾伯维新闻中，执行副总裁 Azita Saleki-Gerhardt 于 8 月 12 日出售了 42,370 股该公司的股票。该股票以平均价格 198.42 美元出售，总价值为 8,407,055.40 美元。交易完成后，该执行副总裁直接持有 177,292 股该公司的股票，价值 35,178,278.64 美元。此交易代表其持股减少了 19.29%。该交易已在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。此外，执行副总裁 Nicholas Donoghoe 于 8 月 5 日出售了 13,295 股该公司的股票。该股票以平均价格 198.51 美元出售，总交易额为 2,639,190.45 美元。交易完成后，该执行副总裁直接持有 58,247 股该公司的股票，价值约 11,562,611.97 美元。这代表其持股减少了 18.58%。该销售的披露信息可在此处找到。公司内部人士目前持有 0.25% 的股票。</p>
<h2>艾伯维公司简介</h2>
<p>（免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药物包括：Humira，一种用于自身免疫性疾病和肠道贝赫切特病及脓疱性坏死性皮肤病的注射剂；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；以及 Venclexta/Venclyxto，用于治疗血癌。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比艾伯维更好的股票</li>
<li>投资者如何识别并成功交易下跌缺口股票</li>
<li>通用动力创下新高：为什么它可能会继续上涨</li>
<li>如何计算股票利润</li>
<li>耐克的逆转：如果鞋子合适，就买下它！</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>英伟达突破新高：接下来会发生什么？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

高盛

<p>Capital & Planning LLC 已将其在艾伯维（AbbVie Inc.，NYSE:ABBV）的持股比例减少了 81.2%，出售了 5,000 股，保留了 1,155 股，价值 214,000 美元。其他机构投资者，包括先锋集团（Vanguard）和高盛（Goldman Sachs），则增加了在艾伯维的持股。分析师们提高了对艾伯维的目标价，普遍评级为 “适度买入”，目标价为 223.52 美元。艾伯维的股票开盘价为 236.98 美元，12 个月的价格区间为 163.81 美元至 244.81 美元。该公司报告上个季度每股收益为 2.97 美元，未达到预期，但收入同比增长了 6.6%</p>

<p>Capital &amp; Planning LLC trimmed its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 81.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,155 shares of the company's stock after selling 5,000 shares during the quarter. Capital &amp; Planning LLC's holdings in AbbVie were worth $214,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Capital &amp; Planning LLC 在最近向美国证券交易委员会提交的 13F 文件中表示，在第二季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股减少了 81.2%。该公司在季度内出售了 5,000 股后，持有 1,155 股艾伯维的股票。根据其最近的 SEC 文件，Capital &amp; Planning LLC 在艾伯维的持股价值为 214,000 美元。</p>
</div><ul>
<li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li>
</ul>
<div class="lb-trans"><ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in AbbVie by 0.5% in the first quarter. Vanguard Group Inc. now owns 173,917,865 shares of the company's stock valued at $36,439,271,000 after buying an additional 845,787 shares during the period. Northern Trust Corp raised its stake in AbbVie by 0.9% in the first quarter. Northern Trust Corp now owns 22,013,920 shares of the company's stock valued at $4,612,357,000 after buying an additional 189,294 shares during the period. Goldman Sachs Group Inc. raised its stake in AbbVie by 31.6% in the first quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company's stock valued at $3,068,820,000 after buying an additional 3,519,187 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in AbbVie by 5.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 12,771,854 shares of the company's stock valued at $2,675,959,000 after acquiring an additional 713,148 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in AbbVie by 0.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 9,413,033 shares of the company's stock valued at $1,972,050,000 after acquiring an additional 45,871 shares during the period. 70.23% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也调整了对该公司的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在艾伯维的持股增加了 0.5%。先锋集团目前持有 173,917,865 股艾伯维的股票，价值 36,439,271,000 美元，此前在该期间又购买了 845,787 股。北方信托公司（Northern Trust Corp）在第一季度将其在艾伯维的持股增加了 0.9%。北方信托公司目前持有 22,013,920 股艾伯维的股票，价值 4,612,357,000 美元，此前在该期间又购买了 189,294 股。高盛集团（Goldman Sachs Group Inc.）在第一季度将其在艾伯维的持股增加了 31.6%。高盛集团目前持有 14,646,908 股艾伯维的股票，价值 3,068,820,000 美元，此前在该期间又购买了 3,519,187 股。瑞银资产管理（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度将其在艾伯维的持股增加了 5.9%。瑞银资产管理目前持有 12,771,854 股艾伯维的股票，价值 2,675,959,000 美元，此前在该期间又收购了 713,148 股。最后，Dimensional Fund Advisors LP 在第一季度将其在艾伯维的持股增加了 0.5%。Dimensional Fund Advisors LP 目前持有 9,413,033 股艾伯维的股票，价值 1,972,050,000 美元，此前在该期间又收购了 45,871 股。70.23% 的股票由机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>A number of research firms recently weighed in on ABBV. Wells Fargo &amp; Company increased their price target on AbbVie from $240.00 to $260.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, September 12th. Berenberg Bank raised shares of AbbVie from a &#34;hold&#34; rating to a &#34;buy&#34; rating and increased their price objective for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. Cantor Fitzgerald increased their price objective on shares of AbbVie from $215.00 to $245.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, September 15th. Evercore ISI increased their price target on shares of AbbVie from $207.00 to $222.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, September 22nd. Finally, Piper Sandler started coverage on shares of AbbVie in a report on Tuesday, August 12th. They issued an &#34;overweight&#34; rating and a $231.00 price target on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, AbbVie has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $223.52.</p>
<div class="lb-trans"><p>多家研究公司最近对 ABBV 进行了评估。富国银行（Wells Fargo &amp; Company）在 9 月 12 日的研究报告中将艾伯维的目标股价从 240.00 美元上调至 260.00 美元，并给予该公司 “增持” 评级。贝伦贝格银行（Berenberg Bank）在 9 月 17 日的研究报告中将艾伯维的评级从 “持有” 上调至 “买入”，并将其目标股价从 170.00 美元上调至 270.00 美元。Cantor Fitzgerald 在 9 月 15 日的研究报告中将艾伯维的目标股价从 215.00 美元上调至 245.00 美元，并给予该公司 “增持” 评级。Evercore ISI 在 9 月 22 日的报告中将艾伯维的目标股价从 207.00 美元上调至 222.00 美元，并给予该公司 “跑赢大盘” 评级。最后，派珀·桑德勒（Piper Sandler）在 8 月 12 日的报告中开始覆盖艾伯维的股票。他们给予 “增持” 评级，并设定 231.00 美元的目标股价。四位股票研究分析师对该股票给予强烈买入评级，十七位给予买入评级，八位给予持有评级。根据 MarketBeat 的数据，艾伯维的共识评级为 “适度买入”，共识目标价为 223.52 美元。</p>
</div><ul>
<li>AbbVie Stock Eyes Breakout as Pipeline and Profits Grow</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维股票关注突破，管道与利润增长</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on ABBV</strong></p>
<div class="lb-trans"><p><strong>获取我们对 ABBV 的最新股票分析</strong></p>
</div><h2>AbbVie Stock Down 3.0%</h2>
<div class="lb-trans"><h2>艾伯维股票下跌 3.0%</h2>
</div><p>Shares of ABBV opened at $236.98 on Friday. AbbVie Inc. has a 12 month low of $163.81 and a 12 month high of $244.81. The firm's 50 day moving average is $209.90 and its 200-day moving average is $195.87. The stock has a market capitalization of $418.63 billion, a PE ratio of 112.85, a P/E/G ratio of 1.43 and a beta of 0.51. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.</p>
<div class="lb-trans"><p>艾伯维（ABBV）股票在周五开盘价为 236.98 美元。艾伯维公司 12 个月低点为 163.81 美元，12 个月高点为 244.81 美元。该公司的 50 日移动平均线为 209.90 美元，200 日移动平均线为 195.87 美元。该股票的市值为 4186.3 亿美元，市盈率为 112.85，市盈增长比率为 1.43，贝塔值为 0.51。该公司的流动比率为 0.74，速动比率为 0.61，债务与股本比率为 44.14。</p>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing the consensus estimate of $3.24 by ($0.27). AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. During the same period in the prior year, the business posted $2.65 earnings per share. The firm's revenue for the quarter was up 6.6% compared to the same quarter last year. Equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日宣布了其财报。该公司报告本季度每股收益为 2.97 美元，低于共识预期的 3.24 美元，差额为 0.27 美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。该公司本季度的收入为 154.2 亿美元，而共识预期为 149.3 亿美元。去年同期，该公司的每股收益为 2.65 美元。与去年同期相比，该公司的季度收入增长了 6.6%。股票研究分析师预测，艾伯维公司今年将发布 12.31 美元的每股收益。</p>
</div><h2>AbbVie Announces Dividend</h2>
<div class="lb-trans"><h2>艾伯维宣布分红</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Wednesday, October 15th will be given a $1.64 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie's dividend payout ratio (DPR) is presently 312.38%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，将于 11 月 14 日（星期五）支付。10 月 15 日（星期三）的登记投资者将获得 1.64 美元的分红。除息日为 10 月 15 日（星期三）。这代表着年化分红为 6.56 美元，分红收益率为 2.8%。艾伯维的分红支付比率（DPR）目前为 312.38%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares of the company's stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of the firm's stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the completion of the transaction, the executive vice president directly owned 58,247 shares in the company, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他艾伯维新闻中，执行副总裁 Azita Saleki-Gerhardt 于 8 月 12 日出售了 42,370 股该公司的股票。该股票以平均价格 198.42 美元出售，总价值为 8,407,055.40 美元。交易完成后，该执行副总裁直接持有 177,292 股该公司的股票，价值 35,178,278.64 美元。此交易代表其持股减少了 19.29%。该交易已在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。此外，执行副总裁 Nicholas Donoghoe 于 8 月 5 日出售了 13,295 股该公司的股票。该股票以平均价格 198.51 美元出售，总交易额为 2,639,190.45 美元。交易完成后，该执行副总裁直接持有 58,247 股该公司的股票，价值约 11,562,611.97 美元。这代表其持股减少了 18.58%。该销售的披露信息可在此处找到。公司内部人士目前持有 0.25% 的股票。</p>
</div><h2>AbbVie Company Profile</h2>
<div class="lb-trans"><h2>艾伯维公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药物包括：Humira，一种用于自身免疫性疾病和肠道贝赫切特病及脓疱性坏死性皮肤病的注射剂；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；以及 Venclexta/Venclyxto，用于治疗血癌。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>General Dynamics Hits New Highs: Why It Might Keep Climbing</li>
<li>How to Calculate Stock Profit</li>
<li>Nike’s Turnaround: If the Shoe Fits, Buy It!</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>NVIDIA Breaks Out to New Highs: What Comes Next?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比艾伯维更好的股票</li>
<li>投资者如何识别并成功交易下跌缺口股票</li>
<li>通用动力创下新高：为什么它可能会继续上涨</li>
<li>如何计算股票利润</li>
<li>耐克的逆转：如果鞋子合适，就买下它！</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>英伟达突破新高：接下来会发生什么？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Capital & Planning LLC 出售了 5,000 股艾伯维公司（AbbVie Inc.）的股票，代码为$ABBV